Drug Trial Radar · NCT07343635
The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea
Last checked: Nov 20, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
186
Planned (sponsor's estimate)
Start
Feb 1, 2026
Primary completion
Jul 1, 2027
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 15, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The efficacy and safety of anti-inflammation treatment (Hirudoid introduction followed by yellow light therapy) combined with tofacitinib and doxycycline in Chinese adult patients with mild to moderate erythematous telangiectatic rosacea: A prospective parallel controlled single-blind cohort study
Conditions
- Erythematotelangiectatic Rosacea
Interventions
DoxycyclineDrug
Doxycycline 100 mg orally once daily
HydroxychloroquineDrug
Hydroxychloroquine 200 mg orally twice daily.
TofacitinibDrug
Tofacitinib 5mg orally twice daily.
Anti-inflammatory Treatment (Hirudoid Introduction Followed by Yellow Light Therapy)Device
Topical application of Hirudoid followed by yellow light therapy (wavelength 590 nm, duration 20 minutes per session, once weekly)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Achievement of IGA treatment success at Week 12Time frame: 0 week、12 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Yiwu, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.